Bladder cancer historical perspective: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Farima Kahe (talk | contribs) No edit summary |
||
| (10 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Bladder cancer}} | {{Bladder cancer}} | ||
{{CMG}}; {{AE}} {{F.K}} | |||
==Overview== | |||
Association between bladder cancer and environmental [[carcinogens]] is first discovered in 1895. First [[cystectomy]] is performed as a treatment for bladder cancer in in 1877. [[Radium]] is first used as a treatment of bladder tumors in 1903[[Neoadjuvant chemotherapy|. Neoadjuvant chemotherapy]] including [[methotrexate]], [[vinblastine]], [[doxorubicin]], and [[cisplatin]] (MVAC) is first described in 1985. FDA approved the use of live bacterium, [[Bacillus Calmette-Guérin]] (BCG) for treatment and prevent the recurrence of superficial [[tumors]] in 1990. | |||
==Historical Perspective== | |||
===Discovery=== | |||
*[[Cystoscope]] was first discovered by Maximilian Nitze, a German urologist, in 1877.<ref name="pmid22487294">{{cite journal |vauthors=Wood JW, Casiano RR |title=Inverted papillomas and benign nonneoplastic lesions of the nasal cavity |journal=Am J Rhinol Allergy |volume=26 |issue=2 |pages=157–63 |date=2012 |pmid=22487294 |pmc=3906506 |doi=10.2500/ajra.2012.26.3732 |url=}}</ref> | |||
*Association between bladder cancer and environmental [[carcinogens]] is first discovered in 1895. | |||
*Urine [[cytology]] is first described in 1945.<ref name="Griffiths2013">{{cite journal|last1=Griffiths|first1=T. R. L.|title=Current perspectives in bladder cancer management|journal=International Journal of Clinical Practice|volume=67|issue=5|year=2013|pages=435–448|issn=13685031|doi=10.1111/ijcp.12075}}</ref> | |||
*Micropapillary bladder cancer is first described in 1982.<ref name="HeudelEl Karak2009">{{cite journal|last1=Heudel|first1=Pierre|last2=El Karak|first2=Fadi|last3=Ismaili|first3=Nabil|last4=Droz|first4=Jean-Pierre|last5=Flechon|first5=Aude|title=Micropapillary bladder cancer: a review of Léon Bérard Cancer Center experience|journal=BMC Urology|volume=9|issue=1|year=2009|issn=1471-2490|doi=10.1186/1471-2490-9-5}}</ref> | |||
*Approximately 356,000 new bladder cancer cases of bladder cancer are reported in 2002 worldwide.<ref name="pmid19219610">{{cite journal |vauthors=Ploeg M, Aben KK, Kiemeney LA |title=The present and future burden of urinary bladder cancer in the world |journal=World J Urol |volume=27 |issue=3 |pages=289–93 |date=June 2009 |pmid=19219610 |pmc=2694323 |doi=10.1007/s00345-009-0383-3 |url=}}</ref> | |||
==Landmark Events in the Development of Treatment Strategies== | |||
*First [[cystectomy]] is performed as a treatment for bladder cancer in in 1877. | |||
*[[Radium]] is first used as a treatment of [[bladder tumors]] in 1903.<ref name="pmid20273482">{{cite journal |vauthors=LENZ M, CAHILL GF |title=The treatment of cancer of the bladder by radium needles |journal=Am J Roentgenol Radium Ther |volume=58 |issue=4 |pages=486–92 |date=October 1947 |pmid=20273482 |doi= |url=}}</ref> | |||
*Early bladder removal surgery includes removing the bladder ([[cystectomy]]) and surrounding tissue where cancer is most likely to spread is performed in 1956.<ref name="pmid21904567">{{cite journal |vauthors=Balar A, Bajorin DF, Milowsky MI |title=Management of invasive bladder cancer in patients who are not candidates for or decline cystectomy |journal=Ther Adv Urol |volume=3 |issue=3 |pages=107–17 |date=June 2011 |pmid=21904567 |pmc=3159398 |doi=10.1177/1756287211407543 |url=}}</ref> | |||
*FDA approves the first [[chemotherapy]] drug [[cisplatin]] for treatment of [[bladder tumors]] in 1978. | |||
*Reconstructive bladder surgery in introduced in 1980-1985. | |||
*[[Neoadjuvant chemotherapy]] including [[methotrexate]], [[vinblastine]], [[doxorubicin]], and [[cisplatin]] (MVAC) is first described in 1985.<ref name="pmid8869093">{{cite journal |vauthors=Sagaster P, Flamm J, Flamm M, Mayer A, Donner G, Oberleitner S, Havelec L, Lepsinger L, Ludwig H |title=Neoadjuvant chemotherapy (MVAC) in locally invasive bladder cancer |journal=Eur. J. Cancer |volume=32A |issue=8 |pages=1320–4 |date=July 1996 |pmid=8869093 |doi= |url=}}</ref> | |||
*Intravesical [[chemotherapy]] using [[mitomycin]] to reduce risk of bladder cancer's recurrence is discovered in 1988.<ref name="pmid26604440">{{cite journal |vauthors=Porten SP, Leapman MS, Greene KL |title=Intravesical chemotherapy in non-muscle-invasive bladder cancer |journal=Indian J Urol |volume=31 |issue=4 |pages=297–303 |date=2015 |pmid=26604440 |pmc=4626913 |doi=10.4103/0970-1591.166446 |url=}}</ref> | |||
*FDA approved the use of live bacterium, [[bacillus Calmette-Guérin]] (BCG) for treatment and prevent the recurrence of [[superficial]] [[tumors]] in 1990.<ref name="pmid22778725">{{cite journal |vauthors=Askeland EJ, Newton MR, O'Donnell MA, Luo Y |title=Bladder Cancer Immunotherapy: BCG and Beyond |journal=Adv Urol |volume=2012 |issue= |pages=181987 |date=2012 |pmid=22778725 |pmc=3388311 |doi=10.1155/2012/181987 |url=}}</ref> | |||
*New [[chemotherapy]] combination regimen including [[gemcitabine]] with [[cisplatin]] is introduced as more effective with less side effects compare to MVAC therapy in 2000.<ref name="pmid17851853">{{cite journal |vauthors=Als AB, Sengelov L, Von Der Maase H |title=Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule? |journal=Acta Oncol |volume=47 |issue=1 |pages=110–9 |date=2008 |pmid=17851853 |doi=10.1080/02841860701499382 |url=}}</ref> | |||
*New technology that helps to detect cancerous tumors in the bladder that are invisible to the naked eye is discovered in 2016. | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category: | [[Category:Disease]] | ||
[[Category:Types of cancer]] | |||
[[Category:Urology]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Nephrology]] | |||
[[Category:Surgery]] | |||
Latest revision as of 15:13, 10 May 2018
|
Bladder cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Bladder cancer historical perspective On the Web |
|
American Roentgen Ray Society Images of Bladder cancer historical perspective |
|
Risk calculators and risk factors for Bladder cancer historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Farima Kahe M.D. [2]
Overview
Association between bladder cancer and environmental carcinogens is first discovered in 1895. First cystectomy is performed as a treatment for bladder cancer in in 1877. Radium is first used as a treatment of bladder tumors in 1903. Neoadjuvant chemotherapy including methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) is first described in 1985. FDA approved the use of live bacterium, Bacillus Calmette-Guérin (BCG) for treatment and prevent the recurrence of superficial tumors in 1990.
Historical Perspective
Discovery
- Cystoscope was first discovered by Maximilian Nitze, a German urologist, in 1877.[1]
- Association between bladder cancer and environmental carcinogens is first discovered in 1895.
- Urine cytology is first described in 1945.[2]
- Micropapillary bladder cancer is first described in 1982.[3]
- Approximately 356,000 new bladder cancer cases of bladder cancer are reported in 2002 worldwide.[4]
Landmark Events in the Development of Treatment Strategies
- First cystectomy is performed as a treatment for bladder cancer in in 1877.
- Radium is first used as a treatment of bladder tumors in 1903.[5]
- Early bladder removal surgery includes removing the bladder (cystectomy) and surrounding tissue where cancer is most likely to spread is performed in 1956.[6]
- FDA approves the first chemotherapy drug cisplatin for treatment of bladder tumors in 1978.
- Reconstructive bladder surgery in introduced in 1980-1985.
- Neoadjuvant chemotherapy including methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) is first described in 1985.[7]
- Intravesical chemotherapy using mitomycin to reduce risk of bladder cancer's recurrence is discovered in 1988.[8]
- FDA approved the use of live bacterium, bacillus Calmette-Guérin (BCG) for treatment and prevent the recurrence of superficial tumors in 1990.[9]
- New chemotherapy combination regimen including gemcitabine with cisplatin is introduced as more effective with less side effects compare to MVAC therapy in 2000.[10]
- New technology that helps to detect cancerous tumors in the bladder that are invisible to the naked eye is discovered in 2016.
References
- ↑ Wood JW, Casiano RR (2012). "Inverted papillomas and benign nonneoplastic lesions of the nasal cavity". Am J Rhinol Allergy. 26 (2): 157–63. doi:10.2500/ajra.2012.26.3732. PMC 3906506. PMID 22487294.
- ↑ Griffiths, T. R. L. (2013). "Current perspectives in bladder cancer management". International Journal of Clinical Practice. 67 (5): 435–448. doi:10.1111/ijcp.12075. ISSN 1368-5031.
- ↑ Heudel, Pierre; El Karak, Fadi; Ismaili, Nabil; Droz, Jean-Pierre; Flechon, Aude (2009). "Micropapillary bladder cancer: a review of Léon Bérard Cancer Center experience". BMC Urology. 9 (1). doi:10.1186/1471-2490-9-5. ISSN 1471-2490.
- ↑ Ploeg M, Aben KK, Kiemeney LA (June 2009). "The present and future burden of urinary bladder cancer in the world". World J Urol. 27 (3): 289–93. doi:10.1007/s00345-009-0383-3. PMC 2694323. PMID 19219610.
- ↑ LENZ M, CAHILL GF (October 1947). "The treatment of cancer of the bladder by radium needles". Am J Roentgenol Radium Ther. 58 (4): 486–92. PMID 20273482.
- ↑ Balar A, Bajorin DF, Milowsky MI (June 2011). "Management of invasive bladder cancer in patients who are not candidates for or decline cystectomy". Ther Adv Urol. 3 (3): 107–17. doi:10.1177/1756287211407543. PMC 3159398. PMID 21904567.
- ↑ Sagaster P, Flamm J, Flamm M, Mayer A, Donner G, Oberleitner S, Havelec L, Lepsinger L, Ludwig H (July 1996). "Neoadjuvant chemotherapy (MVAC) in locally invasive bladder cancer". Eur. J. Cancer. 32A (8): 1320–4. PMID 8869093.
- ↑ Porten SP, Leapman MS, Greene KL (2015). "Intravesical chemotherapy in non-muscle-invasive bladder cancer". Indian J Urol. 31 (4): 297–303. doi:10.4103/0970-1591.166446. PMC 4626913. PMID 26604440.
- ↑ Askeland EJ, Newton MR, O'Donnell MA, Luo Y (2012). "Bladder Cancer Immunotherapy: BCG and Beyond". Adv Urol. 2012: 181987. doi:10.1155/2012/181987. PMC 3388311. PMID 22778725.
- ↑ Als AB, Sengelov L, Von Der Maase H (2008). "Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule?". Acta Oncol. 47 (1): 110–9. doi:10.1080/02841860701499382. PMID 17851853.